fashion -WSS

fashion

author：leisure time 2025-09-30 05:04:03 - browse：1753

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Why health care costs have stayed mostly flat since 2010

focus

explore

WSS

How to protect patients from sexual assault

A new House health package & hospitals’ new site

Listen: Biogen's potential pivot, & Illumina's next chapter

How to keep neuroscience’s past racism from being its future

Keeping primary care docs in field isn't impossible, says AAFP CEO

Violet CEO on training clinicians to promote more inclusive care

explore

fashion

focus

Medical leaders decry Supreme Court decision on affirmative action

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

How one medical school became remarkably diverse

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Violet CEO on training clinicians to promote more inclusive care

Peter Hotez and the public health issue of online harassment

How to keep neuroscience’s past racism from being its future

The cancer drug shortage isn’t new — and neither are the solutions

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

hotspot

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Prime Medicine, Myeloid Therapeutics clash over genome

Listen: Biogen's potential pivot, & Illumina's next chapter

A new House health package & hospitals’ new site

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Crinetics acromegaly drug succeeds in late

focus

entertainment

explore

leisure time